Price: quote on request. Your total cost is quoted in writing per case.
We reply within one business dayGet my quote

Metachromatic leukodystrophy (MLD): US-approved treatments and how Gulf families can access them

Creator: Reserve Meds
Published: 2026-10-17

A plain guide for families in the Gulf, checked against US FDA labels, Gulf drug registers and published medical research.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

Metachromatic leukodystrophy: the short answer

The US FDA has approved one medicine on this page for metachromatic leukodystrophy, each for specific patients. None was found on the Gulf registers we checked. Otherwise the hospital can request a named-patient import. Reserve Meds is a digital health company. We do not diagnose or prescribe.

US FDA-approved medicines on this page: Lenmeldy.
Gulf registration (checked 17 October 2026): see each medicine below.
Legal route: Treatment at a qualified center, after a specialist referral.
Price: Quote on request.

What is metachromatic leukodystrophy?

Metachromatic leukodystrophy (MLD) is an inherited disorder in which fats called sulfatides build up in cells, especially the cells that make myelin, the coating that protects nerves. This causes progressive damage to the white matter of the brain, spinal cord and peripheral nerves.^[1]

The damage leads to a gradual loss of thinking and movement skills, such as walking, and can cause loss of sensation in the hands and feet, seizures, paralysis, loss of speech, blindness and hearing loss. The late infantile form, which affects about 50 to 60 percent of people with MLD, usually appears in the second year of life.^[1]

Leukodystrophies can be hard to diagnose. Doctors use neurological exams, family history, MRI and genetic testing. Because the disease gets worse over time, early diagnosis matters. In the US, one gene therapy is approved for some children who have not yet developed symptoms or have early symptoms.^{[2, 3]}

Metachromatic leukodystrophy in the Gulf

A review of 83 children with leukodystrophies at four tertiary centers in Riyadh found that metachromatic leukodystrophy was the most common type, accounting for 25.3% of cases. The parents were related by blood in 58.5% of families.^[4]

US FDA-approved medicines for metachromatic leukodystrophy

Each medicine below is approved in the US for a specific group of patients. The wording summarizes the current US label. Your specialist decides whether any of them is right for the patient.

Lenmeldy (atidarsagene autotemcel)
FDA-approved for children with pre-symptomatic late infantile, pre-symptomatic early juvenile, or early symptomatic early juvenile MLD. It is a one-time gene therapy made from the child's own blood stem cells and given at a qualified treatment center.^[3]
Given at a qualified treatment center. Gulf registers: Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: not found by brand name in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register.^{[5, 6]}
Country guides: Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, Oman, Lebanon, Iraq, Pakistan

How families in the Gulf can access these medicines

For Lenmeldy. These treatments are made for each patient or need a specialized procedure, so treatment happens at a qualified center. For most Gulf families that means a referral from the treating specialist to a center that can give the treatment. A local hospital can only give it if the manufacturer agrees to supply that hospital and the regulator approves. We cannot promise that a manufacturer will agree.

Who does what

Your treating specialist decides whether a medicine is right for the patient and writes the letter.
The hospital checks local supply, files any import request, and gives the treatment safely.
The national regulator decides whether to approve the import of a medicine that is not registered.
The manufacturer decides where its medicine can be supplied, especially for cell and gene therapies.
Reserve Meds helps organize records, coordinates US supply through our wholesale partner, shipping and updates to your family. We do not give medical advice.

Documents you will usually need

A letter from the treating specialist with the diagnosis, past treatments and why the medicine is being considered
Reports that confirm the diagnosis, such as laboratory, genetic, imaging or pathology results, translated into English where needed
Recent clinic notes and a list of current medicines
For a hospital import request: the prescription, the hospital's request form and the written consent of the patient or guardian
Proof of the US FDA approval and the US prescribing information (we can supply these)

We give you a written timeline estimate once we see the hospital file. The regulator, the treatment center and the manufacturer set their own timelines.

What treatment costs

Quote on request. Your total cost depends on the medicine, the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and temperature-controlled shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. Investigational medicines are only available through a manufacturer's expanded-access program requested by the treating physician; we can explain that route, but we do not supply them.

Ask us about treatment for metachromatic leukodystrophy

Tell us the medicine, your country and a WhatsApp or phone number. We reply within one business day. On WhatsApp we usually reply the same day.

Frequently asked questions

Is there an FDA-approved treatment for metachromatic leukodystrophy?

Yes. The medicine on this page has US FDA approval for specific groups of patients: Lenmeldy. The exact conditions are in each US label and are summarized above. Your specialist decides whether any of them fits.

Is Lenmeldy available in Saudi Arabia or the UAE?

Saudi Arabia: not found by brand name in the SFDA drugs list. Abu Dhabi: not found by brand name in the Abu Dhabi DoH drug code list. Checked 17 October 2026. UAE federal status, Kuwait, Qatar, Bahrain and Oman: not verified in a public register. A listing in Abu Dhabi does not show federal UAE status.

How can a family in the Gulf get Lenmeldy?

It is given at a qualified center. Your specialist refers the patient, the center checks eligibility, and the family plans funding and travel. A local hospital can only give it if the manufacturer agrees to supply it and the regulator approves.

How much does treatment cost?

Quote on request. Your total cost, including the medicine, shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Why does timing matter so much in MLD?

MLD damage builds up over time, and the US gene therapy label covers children before symptoms start or, in the early juvenile form, when symptoms are early. A specialist center decides eligibility after testing.

Is MLD inherited?

Yes. MedlinePlus Genetics describes MLD as an inherited disorder. Genetic counseling can help families understand the risk for brothers, sisters and future children.

Sources for the last two answers: ^{[1, 3]} ^[1]

Sources

Checked on 17 October 2026. Labels, registers and regulator rules change. Your hospital pharmacy confirms the current position before filing.

Metachromatic leukodystrophy by country

This page is general health information, not medical advice. It does not replace a consultation with your doctor.